Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Lexaria Bioscience Corp. 宣佈，該公司預計將在約45天內向美國食品藥品管理局提交其計劃中的美國1b期高血壓臨床試驗的在研新藥申請
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.
藥物遞送平台領域的全球創新者Lexaria Bioscience Corp.（納斯達克股票代碼：LEXXW）（“公司” 或 “Lexaria”）宣佈，該公司預計將在大約45天內向美國食品藥品監督管理局（“FDA”）提交計劃中的美國1b期高血壓臨床試驗的在研新藥（“IND”）申請。
As previously announced, this filing was regrettably delayed while Lexaria awaited overdue documentation from one of its key raw material suppliers. Lexaria is pleased to announce that the supplier in question has updated much of this documentation with Lexaria and directly with...
正如先前宣佈的那樣，令人遺憾的是，在Lexaria等待其主要原材料供應商之一的逾期文...
登入免費觀看全文
登入/註冊